Jaguar Health Declares Special Stock Dividend to Protect Against Shareholder Dilution
Jaguar Health has declared a special stock dividend consisting of Series R Convertible Preferred Stock, payable to eligible common stockholders and warrant holders on October 15, 2026. Each preferred share will automatically convert into five common shares on November 2, 2026, designed to reward shareholders while mitigating potential dilution. The company continues pursuing strategic alternatives and preparing a New Drug Application filing for mid-2027 related to its crofelemer treatment program.
Jaguar Health's special dividend mechanism involves distributing convertible preferred shares to current stockholders and warrant holders, with an automatic conversion feature scheduled roughly three weeks after the initial distribution. This structure allows shareholders to receive new equity while the company pursues other strategic options. The biotech firm is simultaneously advancing its clinical pipeline, with plans to submit regulatory documentation for its crofelemer candidate targeting rare gastrointestinal conditions during the second half of 2027.
The announcement may affect multiple stakeholder groups differently. Existing shareholders could benefit from additional equity stakes, though the automatic conversion structure could impact stock price dynamics near the conversion date. Potential investors evaluating the company face uncertainty around both the strategic alternatives being pursued and the clinical development timeline. Patients with rare intestinal diseases may be indirectly affected if regulatory progress toward crofelemer approval accelerates, though the mid-2027 filing target remains provisional and subject to change.